Brenda Kwambana-Adams
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Brenda Kwambana-Adams has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Anne von Gottberg
Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service , Johannesburg
1 shared publication - Augusto Messa
Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique
1 shared publication Caroline Trotter
Disease Dynamics Unit, Department of Veterinary Medicine, University of Cambridge, Cambridge, UK
1 shared publication- David Litt
Respiratory and Vaccine Preventable Bacteria Reference Unit, UK Health Security Agency, 61 Colindale, NW9 5EQ London, United Kingdom; Immunisation and Vaccine Preventable Diseases, UK Health Security Agency, 61 Colindale, NW9 5EQ London, United Kingdom
1 shared publication - Fatima Serhan
World Health Organization, 1202 Geneva, Switzerland
1 shared publication - Goitom Weldegebriel
Immunization, Technical Officer of Surveillance for Vaccine-Preventable Disease World Health Organization, Harare, Zimbabwe, Harare, Zimbabwe, Zimbabwe
1 shared publication
Latest Publications
- 22 April 2024
- Published by Springer Nature in Nature Medicine
- Vol. 30 (6) , 1515-1516
Strategies for controlling pneumococcal disease and outbreaks during humanitarian emergencies
- 22 April 2024
- Published by Springer Nature in Nature Medicine
- Vol. 30 (6) , 1515-1516
Strategies for controlling pneumococcal disease and outbreaks during humanitarian emergencies
- Open Access
- 14 August 2023
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 8 (8) , 413
Evaluation of Laboratories Supporting Invasive Bacterial Vaccine-Preventable Disease (IB-VPD) Surveillance in the World Health Organization African Region, through the Performance of Coordinated External Quality Assessment
(1) Background: Laboratories supporting the invasive bacteria preventable disease (IB-VPD) network are expected to demonstrate the capacity to identify the main etiological agents of pediatric bacterial meningitis (PBM) (Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae) on Gram stains and in phenotypic identification. Individual reports of sentinel site (SSL), national (NL) and regional reference (RRL) laboratories participating in the World Health Organization (WHO)-coordinated external quality assessment, distributed by the United Kingdom National External Quality Assessment (EQA) Services (UK NEQAS) for Microbiology between 2014 and 2019 were analyzed. (2) Methods: The panels consisted of (1) unstained bacterial smears for Gram staining, (2) viable isolates for identification and serotyping/serogrouping (ST/SG) and (3) simulated cerebral spinal fluid (CSF) samples for species detection and ST/SG using polymerase chain reaction (PCR). SSLs and NLs tested for Gram staining and species identification (partial panel). RRLs, plus any SSLs and NLs (optionally) also analyzed the simulated CSF samples (full panel). The passing score was ≥75% for NLs and SSLs, and ≥90% for RRLs and NLs/SSLs testing the full panel. (3) Results: Overall, 63% (5/8) of the SSLs and NLs were able to correctly identify the targeted pathogens, in 2019; but there were challenges to identify Haemophilus influenzae either on Gram stains (35% of the labs failed 2014), or in culture. Individual performance showed inconsistent capacity, with only 39% (13/33) of the SSLs/NLs passing the EQA exercise throughout all surveys in which they participated. RRLs performed well over the study period, but one of the two failed to reach the minimal passing score in 2016 and 2018; while the SSLs/NLs that optionally tested the full panel scored between 75% and 90% (intermediate pass category). (4) Conclusions: We identified a need for implementing a robust quality management system for timely identification of the gaps and then implementing corrective and preventive actions, in addition to continuous refresher training in the SSLs and NLs supporting the IB-VPD surveillance in the World Health Organization, Regional Office for Africa (WHO AFRO).
- 14 August 2023
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 8 (8) , 413
Open AccessEvaluation of Laboratories Supporting Invasive Bacterial Vaccine-Preventable Disease (IB-VPD) Surveillance in the World Health Organization African Region, through the Performance of Coordinated External Quality Assessment
(1) Background: Laboratories supporting the invasive bacteria preventable disease (IB-VPD) network are expected to demonstrate the capacity to identify the main etiological agents of pediatric bacterial meningitis (PBM) (Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae) on Gram stains and in phenotypic identification. Individual reports of sentinel site (SSL), national (NL) and regional reference (RRL) laboratories participating in the World Health Organization (WHO)-coordinated external quality assessment, distributed by the United Kingdom National External Quality Assessment (EQA) Services (UK NEQAS) for Microbiology between 2014 and 2019 were analyzed. (2) Methods: The panels consisted of (1) unstained bacterial smears for Gram staining, (2) viable isolates for identification and serotyping/serogrouping (ST/SG) and (3) simulated cerebral spinal fluid (CSF) samples for species detection and ST/SG using polymerase chain reaction (PCR). SSLs and NLs tested for Gram staining and species identification (partial panel). RRLs, plus any SSLs and NLs (optionally) also analyzed the simulated CSF samples (full panel). The passing score was ≥75% for NLs and SSLs, and ≥90% for RRLs and NLs/SSLs testing the full panel. (3) Results: Overall, 63% (5/8) of the SSLs and NLs were able to correctly identify the targeted pathogens, in 2019; but there were challenges to identify Haemophilus influenzae either on Gram stains (35% of the labs failed 2014), or in culture. Individual performance showed inconsistent capacity, with only 39% (13/33) of the SSLs/NLs passing the EQA exercise throughout all surveys in which they participated. RRLs performed well over the study period, but one of the two failed to reach the minimal passing score in 2016 and 2018; while the SSLs/NLs that optionally tested the full panel scored between 75% and 90% (intermediate pass category). (4) Conclusions: We identified a need for implementing a robust quality management system for timely identification of the gaps and then implementing corrective and preventive actions, in addition to continuous refresher training in the SSLs and NLs supporting the IB-VPD surveillance in the World Health Organization, Regional Office for Africa (WHO AFRO).
- 19 July 2023
- Published by Elsevier in The Lancet Neurology
- Vol. 22 (8) , 646-648
Global burden of meningitis and implications for strategy
- 19 July 2023
- Published by Elsevier in The Lancet Neurology
- Vol. 22 (8) , 646-648
Global burden of meningitis and implications for strategy